Angiotensin-converting enzyme in innate and adaptive immunity

Nature Reviews Nephrology

Volumn 14, Issue 5, 2018, Pages 325-336

  Bernstein, Kenneth E ^a   Khan, Zakir ^a   Giani, Jorge F ^a   Cao, Duo Yao ^a   Bernstein, Ellen A ^a   Shen, Xiao Z ^b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; SUPEROXIDE;

ADAPTIVE IMMUNITY; BACTERICIDAL ACTIVITY; BLOOD PRESSURE REGULATION; BONE MARROW CELL; ENZYME ACTIVE SITE; ENZYME ACTIVITY; HUMAN; INFECTION; INNATE IMMUNITY; KIDNEY DEVELOPMENT; MACROPHAGE FUNCTION; MALIGNANT NEOPLASM; NEUTROPHIL; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCTION; REVIEW; ANIMAL; IMMUNOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY, INNATE; PEPTIDYL-DIPEPTIDASE A;

EID: 85045571237     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2018.15     Document Type: Review

References (107)

1. Skeggs, L. T. Jr. Discovery of the two angiotensin peptides and the angiotensin converting enzyme. Hypertension 21, 259-260 (1993)
2. Skeggs, L. T. Jr., Marsh, W. H., Kahn, J. R. & Shumway, N. P. The existence of two forms of hypertensin. J. Exp. Med. 99, 275-282 (1954)
3. Metzger, R. et al. Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: vessel, organ and species specificity. Microvasc. Res. 81, 206-215 (2011)
4. Bernstein, K. E. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol. Rev. 65, 1-46 (2012)
5. Rigat, B. et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86, 1343-1346 (1990)
6. Dux, S. et al. Serum angiotensin converting enzyme activity in normal adults and patients with different types of hypertension. Isr. J. Med. Sci. 20, 1138-1142 (1984)
7. Bénéteau-Burnat, B., Baudin, B., Morgant, G., Baumann, F. C. & Giboudeau, J. Serum angiotensin-converting enzyme in healthy and sarcoidotic children: comparison with the reference interval for adults. J. Clin. Chem. 36, 344-346 (1990)
8. Cushman, D. W. & Ondetti, M. A. History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 17, 589-592 (1991)
9. Mentz, R. J. et al. The past, present and future of renin-angiotensin aldosterone system inhibition. Int. J. Cardiol. 167, 1677-1687 (2013)
10. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316, 1429-1435 (1987)
11. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991)
12. Lieberman, J. Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am. J. Med. 59, 365-372 (1975)
13. Silverstein, E., Pertschuk, L. P. & Friedland, J. Immunofluorescent localization of angiotensin converting enzyme in epithelioid and giant cells of sarcoidosis granulomas. Proc. Natl Acad. Sci. USA 76, 6646-6648 (1979)
14. Smithies, O., Kim. H. S., Takahashi, N. & Edgell, M. H. Importance of quantitative genetic variations in the etiology of hypertension. Kidney Int. 58, 2265-2280 (2000)
15. Kim, S. & Iwao, H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol. Rev. 52, 11-34 (2000)
16. Krege, J. H. et al. Male-female differences in fertility and blood pressure in ACE deficient mice. Nature 375, 146-148 (1995)
17. Esther, C. R. Jr. et al. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced Male fertility. Lab. Invest. 74, 953-965 (1996)
18. Gribouval, O. et al. Spectrum of mutations in the renin-angiotensin system genes in autosomal recessive renal tubular dysgenesis. Hum. Mutat. 33, 316-326 (2012)
19. Ertoy, D. & Bernstein, K. E. in Drugs, Enzymes and Receptors of the Renin-Angiotensin System: Celebrating a Century of Discovery (eds Husain, A. & Graham, R.) 205-223 (Harwood Academic Publishers, The Netherlands, 2000)
20. Kim, H. S. et al. Genetic control of blood pressure and the angiotensinogen locus. Proc. Natl Acad. Sci. USA 92, 2735-2739 (1995)
21. Yanai, K. et al. Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice. J. Biol. Chem. 275, 5-8 (2000)
22. Tsuchida, S. et al. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J. Clin. Invest. 101, 755-760 (1998)
23. Miyazaki, Y. et al. Angiotensin induces the urinary peristaltic machinery during the perinatal period. J. Clin. Invest. 102, 1489-1497 (1998)
24. Fuchs, S. et al. Male fertility is dependent on dipeptidase activity of testis ACE. Nat. Med. 11, 1140-1142 (2005)
25. Li, L. J. et al. Human sperm devoid of germinal angiotensin-converting enzyme is responsible for total fertilization failure and lower fertilization rates by conventional in vitro fertilization. Biol. Reprod. 90 125, 1-7 (2014)
26. Hagaman, J. R. et al. Angiotensin-converting enzyme and Male fertility. Proc. Natl Acad. Sci. USA 95, 2552-2557 (1998)
27. Ramaraj, P., Kessler, S. P., Colmenares, C. & Sen, G. C. Selective restoration of Male fertility in mice lacking angiotensin-converting enzymes by sperm-specific expression of the testicular isozyme. J. Clin. Invest. 102, 371-378 (1998)
28. Marchesi, C., Paradis, P. & Schiffrin, E. L. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 29, 367-374 (2008)
29. Benigni, A., Cassis, P. & Remuzzi, G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol. Med. 2, 247-257 (2010)
30. Montezano, A. C., Nguyen Dinh Cat, A., Rios, F. J. & Touyz, R. M. Angiotensin II and vascular injury. Curr. Hypertens. Rep. 16, 431 (2014)
31. Mateo, T. et al. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J. Immunol. 176, 5577-5586 (2006)
32. Nathan, C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J. Clin. Invest. 111, 769-778 (2003)
33. Torres, M. & Forman, H. J. Redox signaling and the MAP kinase pathways. Biofactors 17, 287-296 (2003)
34. Biancardi, V. C., Bomfim, G. F., Reis, W. L., Al-Gassimi, S. & Nunes, K. P. The interplay between Angiotensin II, TLR4 and hypertension. Pharmacol. Res. 120, 88-96 (2017)
35. Meng, Y., Chen, C., Liu, Y., Tian, C. & Li, H. H. Angiotensin II regulates dendritic cells through activation of NF-B /p65, ERK1/2 and STAT1 pathways. Cell Physiol. Biochem. 42, 1550-1558 (2017)
36. Hoch, N. E. et al. Regulation of T cell function by endogenously produced angiotensin II. Am. J. Physiol. Reful Integr. Comp. Physiol. 296, R208-R216 (2009)
37. Platten, M. et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1-and TH17-mediated autoimmunity. Proc. Natl Acad. Sci. USA 106, 14948-14953 (2009)
38. Lanz, T. V. et al. Angiotensin II sustains brain inflammation in mice via TGF-beta. J. Clin. Invest. 120, 2782-2794 (2010)
39. Crowley, S.,D. & Rudemiller, N. P. Immunologic Effects of the Renin-Angiotensin System. J. Am. Soc. Nephrol. 28, 1350-1361 (2017)
40. Crowley, S. D. et al. A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension 55, 99-108 (2010)
41. Zhang, J. D. et al. A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ. Res. 110, 1604-1617 (2012)
42. Zhang, J. D. et al. Type 1 angiotensin receptors on macrophages ameliorate IL-1 receptor-mediated kidney fibrosis. J. Clin. Invest. 124, 2198-2203 (2014)
43. Ma, L. J. et al. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am. J. Physiol. Renal Physiol. 300, F1203-F1213 (2011)
44. Brice, E. A., Friedlander, W., Bateman, E. D. & Kirsch, R. E. Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD. Chest 107, 706-710 (1995)
45. Lieberman, J. & Rea, T. H. Serum angiotensin converting enzyme in leprosy and coccidioidomycosis. Ann. Intern. Med. 87, 422-425 (1977)
46. Olle, E. W. et al. Screening of serum samples from Wegener's granulomatosis patients using antibody microarrays. Proteom. Clin. Appl. 1, 1212-1220 (2007)
47. Weinstock, J. V. Production of neuropeptides by inflammatory cells within the granulomas of murine schistosomiasis mansoni. Eur. J. Clin. Invest. 21, 145-153 (1991)
48. Williams, G. T. & Williams, W. J. Granulomatous inflammation - A review. J. Clin. Pathol. 36, 723-733 (1983)
49. Nathan, C. Macrophages' choice: take it in or keep it out. Immunity 45, 710-711 (2016)
50. Ramakrishnan, L. Revisiting the role of the granuloma in tuberculosis. Nat. Rev. Immunol. 12, 352-366 (2012)
51. Sylvius, F. Opera Medica (A. Wolfgang, 1679)
52. Bean, A. G. et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J. Immunol. 162, 3504-3511 (1999)
53. Roach, D. R. et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 168, 4620-4627 (2002)
54. Bouley, D. M., Ghori, N., Mercer, K. L., Falkow, S. & Ramakrishnan, L. Dynamic nature of host-pathogen interactions in Mycobacterium marinum granulomas. Infect. Immun. 69, 7820-7831 (2001)
55. Helming, L. & Gordon, S. The molecular basis of macrophage fusion. Immunobiology 212, 785-793 (2007)
56. Cronan et al. Macrophage epithelial reprogramming underlies mycobacterial granuloma formation and promotes infection. Immunity 45, 861-876 (2016)
57. Shen, X. Z. et al. Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am. J. Pathol. 170, 2122-2134 (2007)
58. Shen, X. Z. et al. Myeloid expression of angiotensin-converting enzyme facilitates myeloid maturation and inhibits the development of myeloid-derived suppressor cells. Lab Invest. 94, 536-544 (2014)
59. Okwan-Duodu, D. et al. Angiotensin-converting enzyme overexpression in mouse myelomonocytic cells augments resistance to Listeria and methicillin-resistant Staphylococcus aureus. J. Biol. Chem. 285, 39051-39060 (2010)
60. Pamer, E. & Cresswell, P. Mechanism of MHC class I resticted antigen processing. Annu. Rev. Immunol. 16, 323-358 (1998)
61. Purcell, A. W. & Elliott, T. Molecular machinations of the MHC-I peptide loading complex. Curr. Opin. Immunol. 20, 75-81 (2008)
62. Shen, X. Z., Lukacher, A. E., Billet, S., Williams, I. R. & Bernstein, K. E. Expression of angiotensin-converting enzyme changes major histocompatibility complex class I peptide presentation by modifying C termini of peptide precursors. J. Biol. Chem. 283, 9957-9965 (2008)
63. Shen, X. Z. et al. The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat. Immunol. 12, 1078-1085 (2011)
64. Gonzalez-Villalobos, R. A. et al. Rediscovering ACE: novel insights into the many roles of the angiotensin converting enzyme. J. Mol. Med. 91, 1143-1154 (2013)
65. Zhao, T., Bernstein, K. E., Fang, J. & Shen, X. Z. Angiotensin-converting enzyme affects the presentation of MHC class II antigens. Lab. Invest. 97, 764-771 (2017)
66. de Oliveira, S., Rosowski, E. E. & Huttenlocher, A. Neutrophil migration in infection and wound repair: going forward in reverse. Nat. Rev. Immunol. 16, 378-391 (2016)
67. Guerra, F. E., Borgogna, T. R., Patel, D. M., Sward, E. W. & Voyich, J. M. Epic immune battles of history: neutrophils versus Staphylococcus aureus. Front. Cell. Infect. Microbiol. 7, 286 (2017)
68. Khan, Z. et al. Angiotensin-converting enzyme enhances the oxidative response and bactericidal activity of neutrophils. Blood 130, 328-339 (2017)
69. Winterbourn, C. C., Kettle, A. J. & Hampton, M. B. Reactive oxygen species and neutrophil function. Annu. Rev. Biochem. 85, 765-792 (2016)
70. Li, P. et al. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J. Exp. Med. 207, 1853-1862 (2010)
71. Remijsen, Q. et al. Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality. Cell Death Differ. 18, 581-588 (2011)
72. Branzk, N. et al. Neutrophils sense microbe size and selectively release neutrophil extracellular traps in response to large pathogens. Nat. Immunol. 15, 1017-1025 (2014)
73. Branzk, N. & Papayannopoulos, V. Molecular mechanisms regulating NETosis in infection and disease. Semin. Immunopathol. 35, 513-530 (2013)
74. Pouwels, K. B., Visser, S. T. & Hak, E. Effect of pravastatin and fosinopril on recurrent urinary tract infections. J. Antimicrob. Chemother. 68, 708-714 (2013)
75. Pouwels, K. B., Bos, J. H. & Hak, E. ACE inhibitors and urinary tract infections. Epidemiology 25, 466-467 (2014)
76. Dial, S., Nessim, S. J., Kezouh, A., Benisty, J. & Suissa, S. Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis. Br. J. Clin. Pharmacol. 78, 1151-1158 (2014)
77. Mortensen, E. M., Restrepo, M. I., Anzueto, A. & Pugh, J. The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia. BMC Pulm. Med. 5, 12 (2005)
78. Mortensen, E. M. et al. Impact of statins and angiotensin converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur. Respir. J. 31, 611-617 (2008)
79. Sobczuk, P., Szczylik, C., Porta, C. & Czarnecka, A. M. Renin angiotensin system deregulation as renal cancer risk factor. Oncol. Lett. 14, 5059-5068 (2017)
80. Pinter, M. & Jain, R. K. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci. Transl Med. 9, eaan5616 (2017)
81. Steinman, L. Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal. Immunol. Res. 58, 307-314 (2014)
82. Lder, F., Lee, D. H., Gold, R., Stegbauer, J. & Linker, R. A. Small but powerful: short peptide hormones and their role in autoimmune inflammation. J. Neuroimmunol. 217, 1-7 (2009)
83. Fahmy Wahba, M. G., Shehata Messiha, B. A. & Abo-Saif, A. A. Ramipril and haloperidol as promising approaches in managing rheumatoid arthritis in rats. Eur. J. Pharmacol. 765, 307-315 (2015)
84. Sagawa, K., Nagatani, K., Komagata, Y. & Yamamoto, K. Angiotensin receptor blockers suppress antigen-specific T-cell responses and ameliorate collagen-induced arthritis in mice. Arthr. Rheumat. 52, 1920-1928 (2005)
85. Bahk, T. J., Daniels, M. D., Leon, J. S., Wang, K. & Engman, D. M. Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis. Int. J. Cardiol. 125, 85-93 (2008)
86. Chang, Y. & Wei, W. Angiotensin II in inflammation, immunity and rheumatoid arthritis. Clin. Exp. Immunol. 179, 137-145 (2015)
87. Martin, M. F. et al. Captopril: a new treatment for rheumatoid arthritis Lancet 1, 1325-1328 (1984)
88. Danilov, S. M. et al. Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp. Hematol. 31, 1301-1309 (2003)
89. Viinikainen, A., Nyman, T., Fyhrquist, F. & Saijonmaa, O. Downregulation of angiotensin converting enzyme by TNF-alpha in differentiating human macrophages. Cytokine 18, 304-310 (2002)
90. Inagami, T. in Biochemical Regulation of Blood Pressure (ed. Soffer, R. L.) 39-72 (John Wiley and Sons, New York, 1981)
91. Sun, X. et al. Catabolic attacks of membrane-bound angiotensin-converting enzyme on the N-terminal part of species-specific amyloid-beta peptides. Eur. J. Pharmacol. 588, 18-25 (2008)
92. Chen, H. L., Lsdorf, H., Hecht, H. J. & Tsai, H. Porcine pulmonary angiotensin I-converting enzyme- biochemical characterization and spatial arrangement of the N-and C-domains by three-dimensional electron microscopic reconstruction. Micron 41, 674-685 (2010)
93. Allinson, T. M. et al. The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur. J. Biochem. 271, 2539-2547 (2004)
94. Parkin, E. T., Turner, A. J. & Hooper, N. M. Secretase-mediated cell surface shedding of the angiotensin-converting enzyme. Protein Pept. Lett. 11, 423-432 (2004)
95. Barauna, V. G., Campos, L. C., Miyakawa, A. A. & Krieger, J. E. ACE as a mechanosensor to shear stress influences the control of its own regulation via phosphorylation of cytoplasmic Ser(1270). PLoS ONE. 6, e22803 (2011)
96. Fleming, I. Signaling by the angiotensin-converting enzyme. Circ. Res. 98, 887-896 (2006)
97. Howard, T. E., Shai, S.-Y., Langford, K. G. & Martin, B. M. & Bernstein, K. E. Transcription of testicular angiotensin-converting enzyme (ACE) is initiated within the 12th intron of the somatic ACE gene. Mol. Cell. Biol. 10, 4294-4302 (1990)
98. Wei, L., Alhenc-Gelas, F., Corvol, P. & Clauser, E. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J. Biol. Chem. 266, 9002-9008 (1991)
99. Fuchs, S. et al. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 51, 267-274 (2008)
100. Rousseau, A. et al. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 270, 3656-3661 (1995)
101. Zhu, L. et al. Ac-SDKP suppresses TNF-induced ICAM-1 expression in endothelial cells via inhibition of IB kinase and NF-B activation. Am. J. Physiol. Heart Circ. Physiol. 310, H1176-H1183 (2016)
102. Hubert, C., Houot, A. M., Corvol, P. & Soubrier, F. Structure of the angiotensin I-converting enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J. Biol. Chem. 266, 15377-15383 (1991)
103. [No authors listed.] Alzheimer's Disease Facts and Figures. Alzheimer's Association https://www.alz.org/facts/(2017)
104. Alzheimer's Association. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 12, 459-509 (2016)
105. Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8, 595-608 (2016)
106. Schwartz, M. Can immunotherapy treat neurodegeneration Science 357, 254-255 (2017)
107. Bernstein, K. E. et al. Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline. J. Clin. Invest. 124, 1000-1012 (2014).